Lucentis(R) (Ranibizumab) Launched For Vision Loss Due To Diabetic Macular Oedema, A Serious And Common Complication Of Diabetes
Novartis Pharmaceuticals UK Ltd announced that Lucentis® (ranibizumab) has launched in the UK for the treatment of visual impairment due to diabetes, specifically diabetic macular oedema (DMO). This offers fresh hope for people with this serious and common complication of diabetes. Until now, laser treatment has been the current standard treatment but has not been shown to improve vision...